Home > Press > Oxonica Completes £2.6 million Rights Issue
The Group has raised approximately £2.6 million through the issue of 38,478 new ordinary shares £67.89 per share.
Oxonica Completes £2.6 million Rights Issue and Employee Subscription
February 7, 2005
Oxonica Limited, a leading European group developing commercial solutions based on nanotechnology, announces today that it has completed a further round of financing, through a Rights Issue and Employee Subscription.
The Group has raised approximately £2.6 million through the issue of 38,478 new ordinary shares £67.89 per share. This includes 2,006 shares issued to employees who were invited to subscribe for shares at the Rights Issue price. The issue was substantially underwritten by Seighford Investment Company Limited and Mr Richard Farleigh, both of whom were founder investors in Oxonica and was well supported by the Group’s shareholders, including the three largest investors; BASF Venture Capital GmbH, Foresight Technology VCT and TriVest VCT.
As well as raising additional funds, the Rights Issue triggered a previously agreed restructuring of the Group’s share capital as a result of which Oxonica now has a single class of ordinary shares.
The greater part of the proceeds will be used to provide working capital and to support the global commercial roll-out of the Group’s market leading products; Envirox (Tm) Fuel Borne Catalyst and Optisol (TM) UV Absorber. Envirox has already been adopted by Stagecoach Group plc for use in its UK bus fleet and an agreement has also been signed with DMX Technology Corp to distribute the product into premium branded diesel fuel in the Philippines, in partnership with BASF. Optisol has been selected by Boots Group as the UV filter for incorporation into their new range of Soltan Facial Suncare products.
Commenting on the Rights Issue, Dr Kevin Matthews, Oxonica’s Chief Executive said:
“We are delighted with the response to the Rights Issue, particularly as it demonstrates a high degree of confidence on the part of both shareholders and employees in Oxonica as it begins the full-scale, global commercialisation of a number of key technologies.”
Richard Clarke, Oxonica’s CFO added:
“Following the Rights Issue and associated restructuring, Oxonica now has a straightforward capital structure, which will facilitate future corporate development. Most importantly, it has successfully raised funds to take the company to the next stage of growth.”
+44 1865 856700
Island House, Forest Road, Guernsey, GY8 0AB, UK
+44 (0) 1481 233080
Fax +44 (0) 1481 233082
Copyright © Oxonica
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Arrowhead to Present at Barclays Global Healthcare Conference March 11th, 2014
Nano Labs Shareholder Update March 8th, 2014
FEI Company Announces Date for Investor Conference Participation March 3rd, 2014
Industrial Nanotech, Inc. Completes On Site Visit by PCAOB Audit Firm - Nears Completion of Audit in Preparation for Move to a Senior Stock Exchange in Late 2014 February 27th, 2014
Can material rivaling graphene be mined out of rocks? Yes, if... March 12th, 2014
Iran Unveils 2 New Nano Drugs for Curing Leishmaniasis, Inflammatory Diseases March 12th, 2014
Iran Produces Self-Cleaning Coatings for Textile Industries March 12th, 2014
Detecting Bioterrorism: Is Chemistry Enough? Los Alamos scientist addresses bioaerosol risks and detection March 12th, 2014
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014
Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 4, 2014 January 15th, 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress January 7th, 2014